Moderna¡¯s COVID-19 vaccine is approved in Korea
By Lee, Hye-Kyung | translator Alice Kang
24.09.13 05:28:58
°¡³ª´Ù¶ó
0
Spikevax JN.1 Inj received accelerated approval in 2 months
The Ministry of Food and Drug Safety (MFDS, Minister: Yu-Kyoung Oh) announced on the 11th that it has authorized the manufacturing and sale of ¡®Spikevax JN.1¡¯ that Moderna Korea applied for.
Like Pfizer's COVID-19 vaccine, which was approved on August 30, Spikevax JN.1 is a vaccine that contains an mRNA designed to express the JN.1 variant antigen as the active ingredient.
It is indicated for the prevention of COVID-19 in persons 12 years of age and older and is administered as a single intramuscular
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)